| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:biontech [2022/12/29 04:12]
liam | pharmaceutical_companies:biontech [2023/04/08 21:42] (current)
liam old revision restored (2022/12/29 04:21) |
|---|
| {{ :pharmaceutical_companies:biontech_logo.svg.png?200|}} | {{ :pharmaceutical_companies:biontech_logo.svg.png?200|}} |
| |
| **BioNTech** is a German biotechnology company based in [[Germany:Mainz]], [[Germany]]. | **BioNTech** is a German biotechnology company based in [[Germany:Mainz]], [[:Germany]]. |
| |
| ===== History ===== | ===== History ===== |
| ==== Founding ==== | ==== Founding ==== |
| |
| BioNTech was founded in 2008 by [[Ugur Sahin]], [[Christoph Huber]] and [[Özlem Türeci]] with a seed investment of €150 million from the Strüngmann family, through its investment vehicle [[AT Impf]], and [[MIG Capital]].((//Amendment No. 3 to Form F-1 Registration Statement.// (2019, October 9). BioNTech; Securities and Exchange Commission. https://web.archive.org/web/20221228202950/https://investors.biontech.de/node/6751/html#toc)) | BioNTech was founded in 2008 by [[:Ugur Sahin]], [[:Christoph Huber]] and [[:Özlem Türeci]] with a seed investment of €150 million from the Strüngmann family, through its investment vehicle [[:AT Impf]], and [[:MIG Capital]].((//Amendment No. 3 to Form F-1 Registration Statement.// (2019, October 9). BioNTech; Securities and Exchange Commission. https://web.archive.org/web/20221228202950/https://investors.biontech.de/node/6751/html#toc)) |
| |
| ==== mRNA research and development ==== | ==== mRNA research and development ==== |
| |
| In August 2018, BioNTech announced that it had entered a "multi-year research and development (R&D) collaboration with [[pharmaceutical_companies:Pfizer]]" to "develop [[mRNA]]-based vaccines for prevention of [[influenza]] (flu)."((Maas, S., Woolford, J., & Alatovic, J. (2018, August 16). //BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza.// BioNTech. https://archive.vn/L9LUP)) Under the terms of the agreement, following BioNTech's completion of a first-in-human clinical study, Pfizer would assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines. BioNTech received $120 million upfront. | In August 2018, BioNTech announced that it had entered a "multi-year research and development (R&D) collaboration with [[pharmaceutical_companies:Pfizer]]" to "develop [[:mRNA]]-based vaccines for prevention of [[:influenza]] (flu)."((Maas, S., Woolford, J., & Alatovic, J. (2018, August 16). //BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza.// BioNTech. https://archive.vn/L9LUP)) Under the terms of the agreement, following BioNTech's completion of a first-in-human clinical study, Pfizer would assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines. BioNTech received $120 million upfront. |
| | |
| | In September 2019, BioNTech received a capital contribution of $55 million from the [[:Bill & Melinda Gates Foundation]], with the option of doubling that investment amount at a later date.((Boehler, M., Schweitzer, G., & May, S. (2019, September 4). //BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs.// BioNTech. https://archive.vn/npENU)) |
| |
| On October 16, 2019, [[:Nature]] published an article describing BioNTech's successes in testing experimental [[:immunotherapy|immunotherapy]] [[:vaccines|vaccines]] for [[:cancer]], and suggested the progress could be applied to solve problems like [[:rabies]] and [[:pandemic influenza]].((Dolgin, E. (2019). //Unlocking the potential of vaccines built on messenger RNA.// Nature, 574(7778), S10–S12. https://doi.org/10.1038/d41586-019-03072-8)) | On October 16, 2019, [[:Nature]] published an article describing BioNTech's successes in testing experimental [[:immunotherapy|immunotherapy]] [[:vaccines|vaccines]] for [[:cancer]], and suggested the progress could be applied to solve problems like [[:rabies]] and [[:pandemic influenza]].((Dolgin, E. (2019). //Unlocking the potential of vaccines built on messenger RNA.// Nature, 574(7778), S10–S12. https://doi.org/10.1038/d41586-019-03072-8)) |
| * [[pharmaceutical_companies:Pfizer]] | * [[pharmaceutical_companies:Pfizer]] |
| * [[pharmaceutical_companies:Sanofi]] | * [[pharmaceutical_companies:Sanofi]] |
| * [[Translational Oncology at the University Medical Center of Johannes Gutenberg University]] (TRON) | * [[:Translational Oncology at the University Medical Center of Johannes Gutenberg University]] (TRON) |
| * [[University of Pennsylvania]] | * [[:University of Pennsylvania]] |
| |
| ==== Investors ==== | ==== Investors ==== |
